Navigation Links
Omeros Commences Initial Public Offering of Common Stock
Date:9/18/2009

ne at (800)-503-4611 or by email: prospectusrequest@list.db.com.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery((TM)) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery((TM)) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.

Forward-looking Statements

This press release contains "forward-lo
'/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3

Related biology technology :

1. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
2. Omeros Appoints New Vice President of Clinical Development
3. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
4. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
5. Omeros and BlueCrest Announce $20 Million Debt Facility
6. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
7. Omeros Appoints David A. Mann to its Board of Directors
8. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
9. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
10. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
11. PCI Biotech Commences Phase I/II Trials of Amphinex(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... immune system identifies the transplanted organ as foreign tissue ... cells, the immune cells that mediate rejection, must first ... to migrate to the transplanted organ. In this issue ... Lakkis and colleagues at the University of Pittsburgh used ... is not required for migration. Instead, these cells must ...
(Date:5/17/2013)... New interactive learning forums ... leaders of the medical device industry at the ... expo, from June 18-20 in Philadelphia ... ) , These all-new MedTech ... practical presentations and implementable solutions on the most ...
(Date:5/17/2013)... Miami, FL (PRWEB) May 17, 2013 Men’s ... at La-roche Posay ) and has been known ... itself. Although some men may be far from puberty, other ... be clogging pores, causing breakouts, and threatening skin with unsightly ... with advice from Men’s Health on how to ...
(Date:5/17/2013)... Tooth decay is an epidemic in American children with 50% ... World Health Organization says that worldwide, 60–90% of ... are the long-term effects of this transmissible infection? , ... oral bacterial imbalance and serious systemic issues like heart disease. ... also 100% preventable? Answer: there has been no way to ...
Breaking Biology Technology:MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... Expand Versatility of DelSite cGMP Polymer, ... (Pink Sheets: CARN) today announced its wholly-owned,subsidiary, ... rights license agreement with a biotechnology company ... DelSite,s,high-molecular-weight anionic polysaccharide which is produced under ...
... 19 /Xinhua-PRNewswire/ -- Shanghai Century (Amex:,SHA), a special ... Co., Ltd (Kelun), China,s largest producer of,intravenous (IV) ... highlights with respect to the consolidated results of,operations ... entity,(Kelun Group) for the first half of 2007. ...
... PARSIPPANY, N.J., Sept. 19 Over 20 new ... Biotech Competitive Intelligence &,Business Analysis" conference in two ... standard for pharmaceutical CI, Business Analysis, and Market,Forecasting ... gather on,October 1-2 to attend the meeting. Competition ...
Cached Biology Technology:Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines 2Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines 3Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 2Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 3Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 4Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 5New Competitive Intelligence Speakers Spark Interest in Pharmaceutical Conference on October 1-2 in NJ 2
(Date:5/17/2013)... Ill. An international team of ... structure and cell movement inside a living frog embryo ... a new method to advance biological research and the ... Northwestern University and the Karlsruher Institut fr Technologie in ... the U.S. Department of Energy,s Argonne National Laboratory, released ...
(Date:5/16/2013)... MARC (Maximizing Access to Research Careers) Program has ... for Developmental Biology (SDB) 72nd Annual Meeting in ... are meant to promote the entry of students, ... mainstream of the basic science community and to ... SDB 2013 Annual Meeting. , Awards are given ...
(Date:5/16/2013)... University scientists have shown a gene involved in neurodegenerative ... function of the circadian clock. , In a ... the gene, called Ataxin-2, keeps the clock responsible for ... gene, the rhythm of the fruit fly,s sleep-wake cycle ... difficult for the fly. , The discovery is ...
Breaking Biology News(10 mins):New X-ray method shows how frog embryos could help thwart disease 2Gene involved in neurodegeneration keeps clock running 2
... in the September issue of the Journal of Lipid ... a role in the rising rate of diabetes, especially in ... is the primary mechanism of inheritance; kids get half their ... just starting to understand additional kinds of inheritance like metabolic ...
... a group of University of Oklahoma researchers began studying ... has plagued the energy industry for decades, they did ... capable of converting hydrocarbons into natural gas. ... hydrocarbon metabolismcan be used to stimulate methane gas production ...
... received a $3.2 million grant from the National ... and mathematical disciplines to stem cell research. In ... experts in fields such as cell and molecular ... breakthroughs from the biology lab into practical and ...
Cached Biology News:OU researchers isolate microorganisms that convert hydrocarbons to natural gas 2OU researchers isolate microorganisms that convert hydrocarbons to natural gas 3$3.2M for Rutgers to apply biology, engineering, physical sciences toward stem cells 2$3.2M for Rutgers to apply biology, engineering, physical sciences toward stem cells 3
Mouse HAI-1 Ectodomain MAb (Clone 199732)...
pETDuet-1 is designed for the coexpression of two target genes....
Human IL-29/IFN-lambda 1 Biotinylated Affinity Purified PAb...
Mouse Laminin-1 MAb (Clone AL-3)...
Biology Products: